Compositions of lipid lowering agents
Patent 6342245 Issued on January 29, 2002. Estimated Expiration Date: 
April 24, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 24, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesApolipoprotein-ଲ synthesis inhibitors Apolipoprotein-B synthesis inhibitors Patent #: 5929075 InventorsAssigneeApplicationNo. 530170 filed on 04/24/2000US Classes:424/451, Capsules (e.g., of gelatin, of chocolate, etc.)424/463, Coated capsules424/464, Tablets, lozenges, or pills424/465, With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.)424/470, Where particles are granulated424/474, Coated pills or tablets424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/493, Containing polysaccharides (e.g., sugars)424/494, Cellulose derivatives424/496, Containing natural gums/resins424/497, Containing solid synthetic polymers514/252.19, Five-membered nitrogen hetero ring attached directly or indirectly to the 1,3-diazine ring by nonionic bonding514/253.09, Five-membered nitrogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding514/254.02, The additional five-membered hetero ring also has chalcogen as a ring member514/254.07, Chalcogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding548/127, 1,2,3-thiadiazoles (including hydrogenated)548/129, Chalcogen bonded directly to ring carbon of the thiadiazole ring548/144, Chalcogen bonded directly to ring carbon of the oxadiazole ring548/182, Chalcogen bonded directly to ring carbon of the thiazole ring548/213, Chalcogen bonded directly to ring carbon of the thiazole ring548/225, Chalcogen bonded directly to ring carbon of the oxazole ring548/228, Chalcogen bonded directly at 5-position of the oxazole ring548/229, Chalcogen bonded directly at 2-position of the oxazole ring548/251, Chalcogen or nitrogen attached directly to the tetrazole ring by nonionic bonding548/255, 1,2,3-triazoles (including hydrogenated)548/263.2, Chalcogen bonded directly to ring carbon of the triazole ring548/311.1Additional hetero ring attached directly or indirectly to the diazole ring by nonionic bonding (e.g., 1,3-dioxolan-2-yl methyl-imidazole, etc.)ExaminersPrimary: Page, Thurman K.Assistant: Di Nola-Baron, Liliana Foreign Patent References
International ClassA61K 009/48Foreign Application Priority Data1997-11-03 EPAbstractThe present invention is concerned with novel pharmaceutical compositions of lipid lowering agents which can be administered to a mammal suffering from hyperlipidemia, obesitas or atherosclerosis, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising a lipid lowering agent and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.Field of SearchChalcogen bonded directly at 2- and 4-positionsAt least three hetero rings containing Ring chalcogen in the five-membered hetero ring 1,3-oxazole ring or 1,3-thiazole ring (including hydrogenated) 1,3-diazole ring (including hydrogenated) 1,2,3-thiadiazoles (including hydrogenated) Chalcogen bonded directly to ring carbon of the thiadiazole ring Chalcogen bonded directly to ring carbon of the thiazole ring Chalcogen bonded directly to ring carbon of the thiazole ring Chalcogen bonded directly to ring carbon of the oxazole ring Chalcogen bonded directly at 5-position of the oxazole ring Chalcogen bonded directly at 2-position of the oxazole ring Chalcogen bonded directly to ring carbon of the triazole ring Chalcogen bonded directly to ring carbon of the oxadiazole ring Chalcogen or nitrogen attached directly to the tetrazole ring by nonionic bonding 1,2,3-triazoles (including hydrogenated) Additional hetero ring attached directly or indirectly to the diazole ring by nonionic bonding (e.g., 1,3-dioxolan-2-yl methyl-imidazole, etc.) Cellulose derivatives Particulate form (e.g., powders, granules, beads, microcapsules, and pellets) Cellulose or derivative Contains solid synthetic resin Capsules (e.g., of gelatin, of chocolate, etc.) Tablets, lozenges, or pills Coated pills or tablets With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.) Coated (e.g., microcapsules) |
| ||||||||||||||
